Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
EINSTEIN–PE Investigators; Büller, HR; Prins, MH; Lensin, AW; Decousus, H; Jacobson, BF; Minar, E; Chlumsky, J; Verhamme, P; Wells, P; Agnelli, G; Cohen, A; Berkowitz, SD; Bounameaux, H; Davidson, BL; Misselwitz, F; Gallus, AS; Raskob, GE; Schellong, S; Segers, A.
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
N Engl J Med. 2012; 366(14):1287-1297
Doi: 10.1056/NEJMoa1113572
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Study Group Members Med Uni Graz:
- Pilger Ernst
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND A fixed-dose regimen of rivaroxaban, an oral factor Xa inhibitor, has been shown to be as effective as standard anticoagulant therapy for the treatment of deep-vein thrombosis, without the need for laboratory monitoring. This approach may also simplify the treatment of pulmonary embolism. METHODS In a randomized, open-label, event-driven, noninferiority trial involving 4832 patients who had acute symptomatic pulmonary embolism with or without deep-vein thrombosis, we compared rivaroxaban (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with standard therapy with enoxaparin followed by an adjusted-dose vitamin K antagonist for 3, 6, or 12 months. The primary efficacy outcome was symptomatic recurrent venous thromboembolism. The principal safety outcome was major or clinically relevant nonmajor bleeding. RESULTS Rivaroxaban was noninferior to standard therapy (noninferiority margin, 2.0; P = 0.003) for the primary efficacy outcome, with 50 events in the rivaroxaban group (2.1%) versus 44 events in the standard-therapy group (1.8%) (hazard ratio, 1.12; 95% confidence interval [CI], 0.75 to 1.68). The principal safety outcome occurred in 10.3% of patients in the rivaroxaban group and 11.4% of those in the standard-therapy group (hazard ratio, 0.90; 95% CI, 0.76 to 1.07; P = 0.23). Major bleeding was observed in 26 patients (1.1%) in the rivaroxaban group and 52 patients (2.2%) in the standard-therapy group (hazard ratio, 0.49; 95% CI, 0.31 to 0.79; P = 0.003). Rates of other adverse events were similar in the two groups. CONCLUSIONS A fixed-dose regimen of rivaroxaban alone was noninferior to standard therapy for the initial and long-term treatment of pulmonary embolism and had a potentially improved benefit-risk profile. (Funded by Bayer HealthCare and Janssen Pharmaceuticals; EINSTEIN-PE ClinicalTrials.gov number,NCT00439777.)
- Find related publications in this database (using NLM MeSH Indexing)
- Administration, Oral -
- Aged -
- Anticoagulants - adverse effects
- Drug Therapy, Combination -
- Enoxaparin - adverse effects
- Female -
- Follow-Up Studies -
- Hemorrhage - chemically induced
- Humans -
- International Normalized Ratio -
- Kaplan-Meier Estimate -
- Male -
- Middle Aged -
- Morpholines - adverse effects
- Pulmonary Embolism - drug therapy
- Recurrence -
- Thiophenes - adverse effects
- Treatment Outcome -
- Vitamin K - antagonists & inhibitors